Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Other Accumulated Expenses (2020 - 2025)

Cardiff Oncology (CRDF) has disclosed Other Accumulated Expenses for 6 consecutive years, with $287000.0 as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses rose 24.78% to $287000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $287000.0 through Dec 2025, up 24.78% year-over-year, with the annual reading at $287000.0 for FY2025, 24.78% up from the prior year.
  • Other Accumulated Expenses hit $287000.0 in Q4 2025 for Cardiff Oncology, up from $228000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $419000.0 in Q1 2025 to a low of $8000.0 in Q3 2022.
  • Historically, Other Accumulated Expenses has averaged $156461.5 across 5 years, with a median of $203000.0 in 2025.
  • Biggest five-year swings in Other Accumulated Expenses: plummeted 80.95% in 2022 and later increased 24.78% in 2025.
  • Year by year, Other Accumulated Expenses stood at $42000.0 in 2021, then tumbled by 80.95% to $8000.0 in 2022, then skyrocketed by 2487.5% to $207000.0 in 2023, then rose by 11.11% to $230000.0 in 2024, then grew by 24.78% to $287000.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for CRDF at $287000.0 in Q4 2025, $228000.0 in Q3 2025, and $203000.0 in Q2 2025.